USPTO 2015–2025 USPTO PatentsView US Corporation

Neuropro Technologies, Inc.

USPTO PatentsView assignee record - 28 granted patents across 2 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Neuropro ranks #11,020 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 2 technology areas.

#11,020
of 49,997 US assignees by volume
48th percentile
by Innovation Score (34.7/100)
22.3
avg claims per patent
+27%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11020 · US Corporation #11,020 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

  • GRANTS-SMALL 28 grants
  • UPPER-Q #11,020/49,997
  • PHOTO-FINISH Nagase ChemteX
  • CPC-NARROW A61F · 2 areas
  • INNOV-THIN 34.7/100
  • CLAIMS-DENSE 22.3 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-UP +27% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nagase ChemteX Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neuropro’s 34.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Neuropro

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Neuropro's Innovation Score is 34.7/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Neuropro?

Each dot is one of Neuropro’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuropro’s own 22.3 claims/patent is ABOVE the 13.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neuropro vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 27.92828.1 510152025 Granted patents (volume) Avg claims / patent Nutramax Laboratories, Inc. - 28, 13.68Nutramax Laborato…Nagase ChemteX Corporation - 28, 10.61Nagase ChemtexNemoto Kyorindo Co., Ltd. - 28, 11.36Nemoto KyorindoNeoChord, Inc. - 28, 18.36NeochordNext Silicon Ltd - 28, 21.25Next SiliconNuCana plc - 28, 15.96NucanaO2 Partners, LLC - 28, 8.82O2 PartnersOndal Medical Systems GMBH - 28, 15.96Ondal Medical Sys…Neuropro Technologies, Inc. - 28, 22.32Neuropro
Neuropro vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neuropro's grants concentrate

Neuropro Technologies, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 96.4% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2018 (5 grants) versus a trough of 1 in 2015. By volume, Neuropro sits between Nutramax Laboratories, Inc. and Ondal Medical Systems GMBH.

Neuropro's three-year grant acceleration

Neuropro Technologies, Inc. shows 7 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Neuropro's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Neuropro holds 28 patents at rank #11,024, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Neuropro

By rank, the assignees closest to #11,024 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Neuropro's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Neuropro, neither rank-band nor same-CPC leaders (those blocks stay above). In A61F (Filters Implantable Into Blood Vessels), Neuropro ranks #238 of 3,082 assignees by patent count in that subclass.

Neuropro's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 48th percentile higher than 48% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Neuropro Technologies, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 3.6%
2016 1 3.6%
2017 1 3.6%
2018 5 17.9%
2019 3 10.7%
2020 5 17.9%
2021 2 7.1%
2022 5 17.9%
2023 1 3.6%
2024 1 3.6%
2025partial year 3 10.7%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Neuropro Technologies, Inc.'s patent record in context - here's where to go next.

  • Neuropro Technologies, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 96.4% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #11,020 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Neuropro Technologies, Inc. against Nutramax Laboratories, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 34.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.